文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

WT1与PRAME过表达预测伴血小板减少的骨髓增生异常综合征患者不良结局

Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.
PubMed 文献 · Blood Adv · 2019-01-01

这项多中心观察性研究纳入中国7家三级医疗中心的1110例伴血小板减少的成人MDS患者,检测诊断时骨髓WT1与PRAME转录本水平。WT1和PRAME过表达与原始细胞比例升高、不良细胞遗传学及更高IPSS-R风险相关,且均为AML演变、总生存和无进展生存的独立不良预后因素。两基因过表达可识别生存显著更差的患者,并可将IPSS-R低危患者分为预后显著不同的低-良好组与低-不良组。

要点

  • WT1和PRAME过表达与伴血小板减少MDS患者的不良临床特征及更高IPSS-R风险相关。
  • WT1和PRAME过表达均为AML演变、总生存和无进展生存的独立不良预后因素。
  • 基于WT1/PRAME转录本水平可将IPSS-R低危患者分为预后显著不同的两组。

核心结论

  • WT1/PRAME转录本分析可提高伴血小板减少MDS患者的预后精确度并改善风险分层。

研究设计与样本

  • 多中心观察性研究,纳入中国7家三级医疗中心伴血小板减少的成人MDS患者,共1110例。
  • 检测诊断时采集的骨髓样本中WT1与PRAME转录本水平,并分析其预后效应。

主要发现

  • WT1和PRAME过表达与原始细胞比例升高、更差细胞遗传学及更高IPSS-R风险相关。
  • WT1和PRAME过表达均为AML演变、总生存和无进展生存的独立不良预后因素。
  • 两基因过表达共同识别出一组生存显著更差的伴血小板减少MDS患者。
  • 基于WT1和PRAME转录本水平,IPSS-R低危患者被分为低-良好组与低-不良组,两组预后显著不同。
  • 低-不良组患者的生存与中危组患者相似。

关键数值与推荐

  • 共纳入1110例伴血小板减少的成人MDS患者。
  • WT1和PRAME过表达与更高IPSS-R风险相关。
  • WT1和PRAME过表达均为AML演变、总生存和无进展生存的独立不良预后因素。
  • IPSS-R低危患者经WT1/PRAME转录本水平分为低-良好组和低-不良组,低-不良组生存与中危组相似。

临床怎么用

  • 对伴血小板减少的MDS患者可检测骨髓WT1和PRAME转录本水平以辅助预后评估。
  • WT1/PRAME过表达提示AML演变、总生存和无进展生存风险更高。
  • 对IPSS-R低危患者,WT1/PRAME转录本水平有助于进一步区分预后不同的亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombocytopenia is associated with life-threatening bleeding and is common in myelodysplastic syndromes (MDS). Robust molecular prognostic biomarkers need to be developed to improve clinical decision making for patients with MDS with thrombocytopenia. Wilms tumor 1 (WT1) and preferentially expressed antigen in melanoma (PRAME) are promising immunogenic antigen candidates for immunotherapy, and their clinical effects on patients with MDS with thrombocytopenia are still not well understood. We performed a multicenter observational study of adult patients with MDS with thrombocytopenia from 7 different tertiary medical centers in China. We examined bone marrow samples collected at diagnosis for WT1 and PRAME transcript levels and then analyzed their prognostic effect for patients with MDS with thrombocytopenia. In total, we enrolled 1110 patients diagnosed with MDS with thrombocytopenia. Overexpression of WT1 and PRAME was associated with elevated blast percentage, worse cytogenetics, and higher Revised International Prognostic Scoring System (IPSS-R) risk. Further, both WT1 and PRAME overexpression were independent poor prognostic factors for acute myeloid leukemia evolution, overall survival, and progression-free survival. Together, the 2 genes overexpression identified a population of patients with MDS with substantially worse survival. On the basis of WT1 and PRAME transcript levels, patients with MDS with IPSS-R low risk were classified into 2 significantly divergent prognostic risk groups: a low-favorable group and a low-adverse group. The low-adverse group had survival similar to that of patients in the intermediate-risk group. Our study demonstrates that the evaluation of WT1/PRAME transcript analysis may improve the prognostication precision and better risk-stratify the patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Huang QS, Wang JZ, Qin YZ, et al. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia. Blood Adv. 2019. PMID: 31714962. doi:10.1182/bloodadvances.2019000564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。